Director David D Davidar sold 25,000 shares of GMED at $80.76 for $2.0M on 2026-06-05, retaining 510.2K shares.
David D Davidar, a GMED director, sold 25,000 shares at $80.76, reducing his non-derivative holdings from 535.2K to 510.2K shares (a -4.7% decrease). GMED's fundamentals remain solid with revenue of $759.9M and net income of $124.3M in the latest quarter, alongside annual revenue growth of +16.6%. Davidar maintains a substantial residual position of 510.2K shares post-transaction, indicating continued significant direct investment in the company. His cross-ticker track record shows 9 prior sells; however, none of his prior same-ticker transactions at GMED have yet reached measurable 90-day outcome points, limiting inference about his timing accuracy at this specific stock. The sale appears consistent with a partial reduction rather than a material change in conviction.